… ProQR Announces Proposed Underwritten Public Offering of … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through … (the “Offering”). All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters a …
… ProQR Announces Proposed Underwritten Public Offering of … & CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated … public offering. All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters a …
… ProQR Announces Proposed Underwritten Public Offering of … and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical … public offering. All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters a …
… ProQR Announces Proposed Underwritten Public Offering of … and CAMBRIDGE, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical … public offering. All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters …
… ProQR Announces Results for the First Quarter of 2017 Key … Investigational new drug (IND) application for QR-110, ProQR’s lead program in ophthalmology, was cleared by the FDA … MD was appointed as Chief Development Strategy Officer of ProQR, and will lead the translational development effort to …
… ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory … a key strategic role in the development and advancement of ProQR’s growing ophthalmology pipeline. LEIDEN, The … chaired by Gerard Platenburg, Chief Innovation Officer of ProQR, now consists of six members including: Drs. Art Levin, …
Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data from Cohort 1 expected by year-end, and target engagemen
… ProQR Announces Third Quarter 2021 Operating and Financial … with Lilly highlights significant potential of ProQR’s Axiomer ® RNA base-editing platform and strengthens … Officer,” said Daniel A. de Boer, Founder and CEO of ProQR. “Theresa is a seasoned leader with deep rare disease …
AX-0810 targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host virtual Investor and Analyst Event in December to highlight translational data and clinical plans for AX-0810, as well as AX-1412, targeting
… ProQR Announces Results for the First Quarter of 2018 Key … RNA editing expert Dr. Peter A. Beal was appointed to ProQR’s scientific advisory board. LEIDEN, the Netherlands, … said Daniel A. de Boer, Chief Executive Officer of ProQR. “Recently, we entered our first corporate partnership …